{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Clear+Cell+Renal+Cell+Carcinoma+Metastatic", "query": { "condition": "Clear Cell Renal Cell Carcinoma Metastatic" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 538, "total_pages": 54, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Clear+Cell+Renal+Cell+Carcinoma+Metastatic&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T03:43:06.587Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00913913", "title": "Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Renal Cell Carcinoma" ], "interventions": [ { "name": "DC vaccine", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "IL-2", "type": "BIOLOGICAL" }, { "name": "IFN", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2009-02", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2015-12-01", "last_synced_at": "2026-05-22T03:43:06.587Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00913913" }, { "nct_id": "NCT00401128", "title": "Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Cleveland Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 9, "start_date": "2004-05", "completion_date": "2007-02", "has_results": false, "last_update_posted_date": "2017-04-20", "last_synced_at": "2026-05-22T03:43:06.587Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00401128" }, { "nct_id": "NCT04588246", "title": "Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Lung Small Cell Carcinoma", "Metastatic Malignant Breast Neoplasm", "Metastatic Malignant Digestive System Neoplasm", "Metastatic Malignant Neoplasm in the Brain", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Renal Cell Carcinoma", "Recurrent Brain Neoplasm", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Memantine", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Stereotactic Radiosurgery", "type": "RADIATION" }, { "name": "Whole-Brain Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "RADIATION" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2021-08-05", "completion_date": "2024-08-06", "has_results": true, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-05-22T03:43:06.587Z", "location_count": 79, "location_summary": "Tucson, Arizona • Corona, California • Duarte, California + 63 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Corona", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04588246" }, { "nct_id": "NCT01392183", "title": "Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "Pazopanib", "type": "DRUG" }, { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Quality of Life Assessment", "type": "BEHAVIORAL" }, { "name": "Benadryl", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 69, "start_date": "2012-10-24", "completion_date": "2019-09-08", "has_results": true, "last_update_posted_date": "2021-09-20", "last_synced_at": "2026-05-22T03:43:06.587Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01392183" }, { "nct_id": "NCT06234605", "title": "A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "HC-7366", "type": "DRUG" }, { "name": "Belzutifan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "HiberCell, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2024-04-29", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-01-15", "last_synced_at": "2026-05-22T03:43:06.587Z", "location_count": 20, "location_summary": "Tucson, Arizona • La Jolla, California • Los Angeles, California + 14 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Lone Tree", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06234605" }, { "nct_id": "NCT01217931", "title": "Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "Pazopanib", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2011-01-19", "completion_date": "2028-01-31", "has_results": false, "last_update_posted_date": "2026-01-30", "last_synced_at": "2026-05-22T03:43:06.587Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01217931" }, { "nct_id": "NCT00005966", "title": "Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "thalidomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2009-02-05", "last_synced_at": "2026-05-22T03:43:06.587Z", "location_count": 11, "location_summary": "Scottsdale, Arizona • South Bend, Indiana • Des Moines, Iowa + 6 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "South Bend", "state": "Indiana" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005966" }, { "nct_id": "NCT03138538", "title": "M8891 First in Human in Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Metastatic Renal Cell Carcinoma" ], "interventions": [ { "name": "Part 1: M8891", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2017-08-08", "completion_date": "2020-09-16", "has_results": true, "last_update_posted_date": "2022-03-11", "last_synced_at": "2026-05-22T03:43:06.587Z", "location_count": 7, "location_summary": "New Haven, Connecticut • Indianapolis, Indiana • Baltimore, Maryland + 4 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03138538" }, { "nct_id": "NCT00418496", "title": "Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cancer", "Melanoma" ], "interventions": [ { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2006-11-08", "completion_date": "2013-10", "has_results": false, "last_update_posted_date": "2017-02-20", "last_synced_at": "2026-05-22T03:43:06.587Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00418496" }, { "nct_id": "NCT03729245", "title": "A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Renal Cell Carcinoma", "Metastatic Renal Cell Carcinoma" ], "interventions": [ { "name": "bempegaldesleukin", "type": "BIOLOGICAL" }, { "name": "sunitinib", "type": "DRUG" }, { "name": "nivolumab", "type": "BIOLOGICAL" }, { "name": "cabozantinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Nektar Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 623, "start_date": "2018-12-18", "completion_date": "2022-10-19", "has_results": true, "last_update_posted_date": "2023-04-11", "last_synced_at": "2026-05-22T03:43:06.587Z", "location_count": 20, "location_summary": "Anchorage, Alaska • Goodyear, Arizona • Little Rock, Arkansas + 16 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03729245" } ] }